Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.98)
# 50
Out of 5,182 analysts
37
Total ratings
81.82%
Success rate
90.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Initiates: Overweight | $12 | $7.21 | +66.44% | 1 | Mar 24, 2026 | |
| ERAS Erasca | Maintains: Overweight | $11 → $18 | $21.49 | -16.24% | 3 | Mar 13, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $120 → $115 | $115.03 | -0.03% | 4 | Feb 26, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $75 → $120 | $135.30 | -11.31% | 2 | Feb 26, 2026 | |
| TNGX Tango Therapeutics | Maintains: Overweight | $11 → $14 | $25.77 | -45.67% | 2 | Jan 16, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $42 → $30 | $15.01 | +99.87% | 2 | Jan 16, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $68.68 | +1.92% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.97 | +169.36% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $5.13 | +367.84% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $10.24 | +114.84% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $128 | $104.50 | +22.49% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $21 | $22.08 | -4.89% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $24.11 | +49.32% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $22.65 | +58.94% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.22 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.52 | +217.46% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.19 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $23.90 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.44 | - | 1 | Oct 31, 2022 |
Relmada Therapeutics
Mar 24, 2026
Initiates: Overweight
Price Target: $12
Current: $7.21
Upside: +66.44%
Erasca
Mar 13, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $21.49
Upside: -16.24%
Arcellx
Feb 26, 2026
Downgrades: Neutral
Price Target: $120 → $115
Current: $115.03
Upside: -0.03%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $75 → $120
Current: $135.30
Upside: -11.31%
Tango Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $11 → $14
Current: $25.77
Upside: -45.67%
Janux Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $42 → $30
Current: $15.01
Upside: +99.87%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $68.68
Upside: +1.92%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.97
Upside: +169.36%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $5.13
Upside: +367.84%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $10.24
Upside: +114.84%
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $104.50
Upside: +22.49%
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $22.08
Upside: -4.89%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $24.11
Upside: +49.32%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $22.65
Upside: +58.94%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.22
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.52
Upside: +217.46%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.19
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $23.90
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.44
Upside: -